Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC

7 Apr 2014

Abstract excerpt

Genome-wide analyses determined previously that the receptor tyrosine kinase (RTK) EPHA2 is commonly overexpressed in non-small cell lung cancers (NSCLCs). EPHA2 overexpression is associated with poor clinical outcomes; therefore, EPHA2 may represent a promising therapeutic target for patients with NSCLC. In support of this hypothesis, here we have shown that targeted disruption of EphA2 in a murine model of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axon Guidance and Neuronal Signaling
Share to HER2/EGFR in Cancer Research
Share to Hippo pathway signaling and YAP/TAZ

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24713656
DOI: 10.1172/jci72522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLCPMID 24713656Read ↗

Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Semantic proximity Read ↗

EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer TherapeuticsSemantic proximity Read ↗

Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung CancerSemantic proximity Read ↗

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.Semantic proximity Read ↗

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1Semantic proximity Read ↗

E2A selectively regulates TGF-β-induced apoptosis in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.Semantic proximity Read ↗

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.Semantic proximity Read ↗

EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion.Semantic proximity Read ↗

Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1.Semantic proximity Read ↗

Effects of cancer-associated EPHA3 mutations on lung cancer.Semantic proximity Read ↗

High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.